Fig. 5.

ROC AUC for circN4BP2L2, CA125 and HE4 in EOC with regard to tumor stage. It contains ROC AUC for circN4BP2L2 comparing early stage EOC with benign (A) and normal (D) cohorts; ROC AUC for CA125 comparing early stage EOC with benign (B) and normal (E) cohorts; ROC AUC for HE4 comparing early stage EOC with benign (C) and normal (F) cohorts; ROC AUC for circN4BP2L2 comparing late stage EOC with benign (G) and normal (J) cohorts; ROC AUC for CA125 comparing late stage EOC with benign (H) and normal (K) cohorts; ROC AUC for HE4 comparing late stage EOC with benign (I) and normal (L) cohorts